What changed from existing technology?
This study creates a tool to predict the outcome of immunotherapy for lung cancer patients using common medical information instead of invasive tests.
The study introduces a new framework that uses common clinical data instead of invasive biomarkers to predict survival risk in lung cancer patients treated with immunotherapy.
Commercialization signals visible at publication
This is not a success probability or investment opinion. It prioritizes follow-up using evidence available when the paper was published.
Verified evidence · 1
ture clinical and regional heterogeneity, leaving many patients inadequately stratified for prognosis. We develop a clinical attribute–based framework that le
Abstract ↗- 시제품·장치 구현 근거 미확인
- 제조·규모 확장 근거 미확인
Later patent, company, clinical, and production events are added separately only after verification.
Patent check: Not checked yetCurrent technology stage: Near commercialization
See what changed before reading the full paper.
What still needs to be solved?
Repeated real-world validation, manufacturability, cost, and long-term stability still require follow-up evidence.
What could change if this succeeds?
This framework could help clinicians better stratify patients for prognosis and treatment planning in immunotherapy for non-small cell lung cancer.
Keep following this technology
Revisit changes when new papers, patents, company participation, validation, or products appear.